Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NewGLAB Therapeutics
Seongnam-si, Gyeonggi-do, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
NewGLAB Therapeutics is a South Korean biotechnology company focused on developing next-generation treatments for metabolic and neurodegenerative diseases. The company leverages its proprietary GLP-1 based multi-agonist platform to create long-acting and highly potent therapies targeting obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis). Beyond metabolic health, NewGLAB is exploring the neuroprotective potential of its pipeline candidates for conditions such as Alzheimer's and Parkinson's disease. By optimizing the pharmacokinetic profiles of incretin mimetics, the company aims to provide more effective and convenient treatment options for patients worldwide.
- Therapeutic areas
- EndocrinologyGastroenterologyNeurologyMetabolic Disorders
- Modalities
- Small moleculePeptideBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on NewGLAB Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NewGLAB Therapeutics.